"We recognize a tremendous need globally for new technologies that will help physicians more quickly and accurately diagnose poorly differentiated and undifferentiated tumors, so that they can determine the optimal therapy for each patient," said Richard Ding, bioTheranostics chief executive officer. "Given Lab21's infrastructure and unique commercial expertise in personalized medicine, we know they are the right partner to deliver the THEROS CancerTYPE ID to doctors and patients in the specified countries."

"The partnership with Lab21 represents the successful transition to our second generation molecular cancer classification technology in Europe. This RT-PCR based test will replace our micro-array based assay, which was licensed to Agendia in Europe," said Ding. "Now through Lab 21, oncologists and pathologists in the specified countries can benefit from the new technology just as their American counterparts."

SOURCE bioTheranostics